Table 1.
Clinical outcomes of NSCLC patients with rare EGFR mutations in exon 18 after EGFRi treatment.
| Mutation | Study (Reference) | EGFR mutation(s), n treated with EGFRi | EGFRi used | ORR (%) | DCR (%) | Median PFS, | Median OS, |
|---|---|---|---|---|---|---|---|
| (CR + PR) | (CR + PR + SD) | months (95% CI) |
months (95% CI) |
||||
| E709X | Wu & Shih [35] | DelE709-T710insD, n = 5 | Gefitinib / Erlotinib | 50.0% | 72.2% | 6.2 | 29.3 |
| E709X complex mutations, n = 13 | |||||||
| Kobayashi & Mitsudomi [8] | DelE709_T710insD, n = 4 | Gefitinib / Erlotinib | 25.0% | 50.0% | NR | NR | |
| E709X complex mutations, n = 15 | 53.0% | 86.7% | NR | NR | |||
| G719X | Chiu et al. [39] | G719X, n = 78 | Gefitinib / Erlotinib | 36.8% | 72.4% | 6.3 | NR |
| G719X + L861Q, n = 9 | 88.9% | 100.0% | 11.9 | NR | |||
| G719X + S768I, n = 10 | 50.0% | 100.0% | |||||
| Kobayashi & Mitsudomi [8] | G719X, n = 148 | Gefitinib / Erlotinib | 65.5% | 32.0% | NR | NR | |
| G719X complex, n = 58 | 59.0% | 89.7% | NR | NR | |||
| Kate et al. [108] | G719X, n = 5 | Gefitinib / Erlotinib | 50.0% | NR | 9.0 (NE) | NR | |
| Xu et al. [40] | G719X, n = 14 | Gefitinib / Erlotinib / Icotinib | 42.9% | 78.6% | 5.98 (1.53 - 10.42) | 19.81 (16.81 - 22.81) | |
| Sequist et al. [21] | G719X, n = 4 | Neratinib | 75.0% | 100.0% | 12.1 | NR | |
| Yang et al. [9] | G719X single, n = 8, + G719X complex, n = 6 | Afatinib | 77.8% | NR | 13.8 (6.8 - NE) | 26.9 (16.4 - NE) | |
| Ahn et al. [112] | G719X n = 19 | Osimertinib | 52.6% | NR | NR | NR | |
| Pooled | Beau-Faller et al. [41] | Total n = 18: G719X, n = 14, E709X, n = 2, | Gefitinib / Erlotinib | 7.0% | 33.3% | 3 (1 - NE) | 22 (1 - 44) |
| rare exon 18 substitutions, n = 2 | |||||||
| Passaro et al. [113] | Total n = 42: G719X, n = 35, E709X, n = 3, | Gefitinib / Erlotinib / Afatinib | 31.0% | 69.0% | 8.3 (4.8 - 11.7) | 17 (8.2 - 25.7) | |
| not specified, n = 4 |
Legend: EGFRi, EGFR inhibitor; ORR, objective response rate; CR, complete response; PR, partial response; DCR, disease control rate; SD, stable disease; PFS, progression-free survival; CI, confidence interval; OS, overall survival; NR, not reported; NE, not estimable.